Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS)

15.92 -0.28 (-1.73%) At close: 03:00PM CST

Zhejiang Jiuzhou Pharmaceutical Co., Ltd

99 Waisha Road
Jiaojiang District
Taizhou 318000
China
86 576 8870 6789
https://www.jiuzhoupharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 4,877

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Lirong Hua	Chairman & GM	N/A	N/A	1968
Mr. Yujie Sha	Financial Manager	N/A	N/A	1980
Mr. Huilu Lin	Deputy GM, Director & Secretary of the Board of Directors	N/A	N/A	1973
Mr. Yi Jiang Mei	Deputy GM & Director	N/A	N/A	1975
Mr. Bin Wang	Director & VP	N/A	N/A	1971
Dr. Yuanqiang Li	Deputy General Manager	N/A	N/A	1967
Mr. Nonggang Yang	Deputy General Manager	N/A	N/A	1976
Ms. Minxia Huang	Deputy General Manager	N/A	N/A	1977
Gong Chen	Vice President	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.

Corporate governance

Zhejiang Jiuzhou Pharmaceutical Co., Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.